Boston Medical Sciences raises ¥5.55bn for AI colorectal screening
The Tokyo company will advance clinical development, regulatory work and preparations for commercialization.
Boston Medical Sciences raised ¥5.55 billion in Series B equity financing on November 13. Japan Growth Capital Investment Corporation, managed by Nomura SPARX Investment, Global Brain and Beyond Next Ventures co-led the round.
The capital will support AI and clinical development, Japanese and US regulatory work, preparations for Japanese commercialization and overseas partnerships. The company is developing CT-based screening that combines virtual bowel cleansing with polyp detection, aiming to reduce the burden of colorectal examinations.
Use of funds
Advance clinical and AI research
Pursue Japanese and US regulatory work
Prepare Japanese commercialization
Develop overseas partnerships